Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
OBJECTIVE
To determine the cost-effectiveness of averting the burden of disease. We used secondary population data and metaanalyses of various government-funded services and interventions to investigate the costs and benefits of various levels of treatment for rheumatoid arthritis (RA) and osteoarthritis (OA) in adults using a burden of disease framework.


METHODS
Population burden was calculated for both diseases in the absence of any treatment as years lived with disability (YLD), ignoring the years of life lost. We then estimated the proportion of burden averted with current interventions, the proportion that could be averted with optimally implemented current evidence-based guidelines, and the direct treatment cost-effectiveness ratio in dollars per YLD averted for both treatment levels.


RESULTS
The majority of people with arthritis sought medical treatment. Current treatment for RA averted 26% of the burden, with a cost-effectiveness ratio of dollar 19,000 per YLD averted. Optimal, evidence-based treatment would avert 48% of the burden, with a cost-effectiveness ratio of dollar 12,000 per YLD averted. Current treatment of OA in Australia averted 27% of the burden, with a cost-effectiveness ratio of dollar 25,000 per YLD averted. Optimal, evidence-based treatment would avert 39% of the burden, with an unchanged cost-effectiveness ratio of dollar 25,000 per YLD averted.


CONCLUSIONS
While the precise dollar costs in each country will differ, the relativities at this level of coverage should remain the same. There is no evidence that closing the gap between evidence and practice would result in a drop in efficiency.
World Health Organization Collaborating Centre for Evidence Health Policy, School of Psychiatry, University of New South Wales at St. Vincent's Hospital, Sydney, Australia. gavina@unsw.edu.au
Gavin
G
Andrews
Leonardo
L
Simonella
Helen
H
Lapsley
Kristy
K
Sanderson
Lyn
L
March
D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics* / Q000628:therapy; D001315:Australia; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D017059:Models, Econometric; D010003:Osteoarthritis / Q000191:economics* / Q000628:therapy
D018501:Antirheumatic Agents